Industry reports
Editor highlights

Search inside this page

Publishers

All regions

Free Market Research Guides to Download

Pathology Analysis & Statistics, May 2013 (p30)

You might be interested in: cancer, breast cancer, prostate cancer, more »

» Purchase Premium Reports

871-920 of about 5 600 reports
Hcl-rhFVIII (Hemophilia A and B) - Forecast and Market Analysis to 2022

Hcl-rhFVIII (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

Hcl-rhFVIII (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant ...

  • Industries : Pathology
Advate (Hemophilia A and B) - Forecast and Market Analysis to 2022

Advate (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

Advate (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII ...

  • Industries : Pathology
  • Countries : Japan, China, World, Argentina, United States, Spain, Italy, France, Germany, United Kingdom, Europe
IB1001 (Hemophilia A and B) - Forecast and Market Analysis to 2022

IB1001 (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

IB1001 (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII ...

  • Industries : Pathology
Kogenate FS (Hemophilia A and B) - Forecast and Market Analysis to 2022

Kogenate FS (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

Kogenate FS (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant ...

  • Industries : Pathology
Alprolix (Hemophilia A and B) - Forecast and Market Analysis to 2022

Alprolix (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

Alprolix (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant ...

  • Industries : Pathology
Xyntha (Hemophilia A and B) - Forecast and Market Analysis to 2022

Xyntha (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

Xyntha (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII ...

  • Industries : Pathology
BAX-817 (Hemophilia A and B) - Forecast and Market Analysis to 2022

BAX-817 (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

BAX-817 (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant ...

  • Industries : Pathology
Recombinate (Hemophilia A and B) - Forecast and Market Analysis to 2022

Recombinate (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

Recombinate (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant ...

  • Industries : Pathology
BeneFix (Hemophilia A and B) - Forecast and Market Analysis to 2022

BeneFix (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

BeneFix (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant ...

  • Industries : Pathology
Rixubis (Hemophilia A and B) - Forecast and Market Analysis to 2022

Rixubis (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

Rixubis (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant ...

  • Industries : Pathology
Novoseven RT (Hemophilia A and B) - Forecast and Market Analysis to 2022

Novoseven RT (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

Novoseven RT (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant ...

  • Industries : Pathology
Eloctate (Hemophilia A and B) - Forecast and Market Analysis to 2022

Eloctate (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

Eloctate (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant ...

  • Industries : Pathology
BAY 94-9027 (Hemophilia A and B) - Forecast and Market Analysis to 2022

BAY 94-9027 (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

BAY 94-9027 (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant ...

  • Industries : Pathology
BAX-855 (Hemophilia A and B) - Forecast and Market Analysis to 2022

BAX-855 (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

BAX-855 (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant ...

  • Industries : Pathology
NovoEight (Hemophilia A and B) - Forecast and Market Analysis to 2022

NovoEight (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

NovoEight (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant ...

  • Industries : Pathology
N8-GP (Hemophilia A and B) - Forecast and Market Analysis to 2022

N8-GP (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

N8-GP (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII ...

  • Industries : Pathology
CSL-627 (Hemophilia A and B) - Forecast and Market Analysis to 2022

CSL-627 (Hemophilia A and B) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • November 2013
  • by Global Data

CSL-627 (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant ...

  • Industries : Pathology
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • November 2013
  • by Global Data

PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022 Summary Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly ...

  • Industries : Pathology
  • Countries : World, India, China, Japan, Spain, Italy, France, Germany, United States, United Kingdom, Europe, Asia
PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • November 2013
  • by Global Data

PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use ...

  • Industries : Pathology
  • Countries : World
BioTime, Inc. (BTX) - Product Pipeline Analysis, 2013 Update

BioTime, Inc. (BTX) - Product Pipeline Analysis, 2013 Update

  • $ 750
  • Company report
  • November 2013
  • by Global Data

Summary BioTime, Inc. (BioTime) is a biomedical company. It undertakes the research, development and manufacture of regenerative medicine and blood plasma volume expanders.. The company is currently developing ...

  • Industries : Pathology
Oxford Biodynamics Limited - Product Pipeline Analysis, 2013 Update

Oxford Biodynamics Limited - Product Pipeline Analysis, 2013 Update

  • $ 750
  • Company report
  • November 2013
  • by Global Data

Summary Oxford Biodynamics Limited (Oxford Bio) is a biotechnology company. The company develops biomarker discovery platform. Its products under clinical development include OBD 27, OBD 29, OBD 35, OBD ...

  • Industries : Pathology
Abnova Corporation (4133) - Product Pipeline Analysis, 2013 Update

Abnova Corporation (4133) - Product Pipeline Analysis, 2013 Update

  • $ 750
  • Company report
  • November 2013
  • by Global Data

Summary Abnova Corporation (Abnova) is a biotechnology company. It manufactures both antibodies and proteins. The company operates through product segments such as DNA & RNA, siRNA/chimera, proteins/peptides, ...

  • Industries : Pathology
BioProtect Ltd. - Product Pipeline Analysis, 2013 Update

BioProtect Ltd. - Product Pipeline Analysis, 2013 Update

  • $ 750
  • Company report
  • November 2013
  • by Global Data

Summary BioProtect Ltd. (BioProtect) is a medical device manufacturing company. The company develops and markets biodegradable balloons for oncology and surgery. Its Bioprotect Balloon Implant protects ...

  • Industries : Pathology
Myanmar Pharmaceuticals and Healthcare Report Q1 2014

Myanmar Pharmaceuticals and Healthcare Report Q1 2014

  • $ 1 300
  • Industry report
  • November 2013
  • by Business Monitor International

Includes 3 FREE quarterly updates BMI View: Despite strong growth potential, Myanmar remains as one of the least attractive country in Asia Pacific due to its small market size and general low spending ...

  • Industries : Pathology
  • Countries : Myanmar
Graymark Healthcare, Inc. (GRMH) - Financial and Strategic SWOT Analysis Review

Graymark Healthcare, Inc. (GRMH) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • November 2013
  • by Global Data

Summary Graymark Healthcare, Inc. (Graymark Healthcare) is the US based pharmacy retailer. The company acquires and operates independent retail pharmacy stores. It offers diagnostic sleep testing services ...

  • Industries : Pathology
  • Countries : United States
Hernia Repair Devices Market (Polymer and Prosthetic Mesh, Biologic Materials, Surgical Instruments and Endoscopy Equipments) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Hernia Repair Devices Market (Polymer and Prosthetic Mesh, Biologic Materials, Surgical Instruments and Endoscopy Equipments) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

  • $ 4 795
  • Industry report
  • November 2013
  • by Transparency Market Research

Hernia occurs as result of protrusion of tissue through an abnormal opening and is affected most commonly to the geriatric population. Hernia is one of the major health concern worldwide. The study analyzes ...

  • Industries : Pathology
  • Countries : World
Actavis SRL  (Romania) - Company Profile

Actavis SRL (Romania) - Company Profile

  • $ 64
  • Company report
  • November 2013
  • by SeeNews - Research & Profiles

Actavis SRL is a Romanian pharmaceutical company, specialising in the production of and trade in pharmaceuticals used in the cancer treatment, the Romanian arm of pharmaceuticals giant Actavis. The company ...

  • Industries : Pathology
  • Countries : Romania
EpiCast Report: Hemophilia - Epidemiology Forecast to 2022

EpiCast Report: Hemophilia - Epidemiology Forecast to 2022

  • $ 3 995
  • Industry report
  • November 2013
  • by Global Data

EpiCast Report: Hemophilia - Epidemiology Forecast to 2022 Summary Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the ...

  • Industries : Pathology
EpiCast Report: Schizophrenia - Epidemiology Forecast to 2022

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2022

  • $ 3 995
  • Industry report
  • November 2013
  • by Global Data

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2022 Summary Schizophrenia is a chronic, severe, and disabling group of psychotic disorders characterized by fundamental disturbances of thinking ...

  • Industries : Pathology
  • Countries : Italy, Japan, World
EpiCast Report: Trigeminal Neuralgia - Epidemiology Forecast to 2022

EpiCast Report: Trigeminal Neuralgia - Epidemiology Forecast to 2022

  • $ 3 995
  • Industry report
  • November 2013
  • by Global Data

EpiCast Report: Trigeminal Neuralgia - Epidemiology Forecast to 2022 Summary Trigeminal neuralgia, also called tic douloureux, is a chronic nerve disorder characterized by severe facial nerve. The condition ...

  • Industries : Pathology
  • Countries : United States, World, Germany, Netherlands, Spain, Norway, Italy, France, Japan, Europe

» View Public Reports

About 12 000 reports

The Australian Pharmaceutical Business Brief

  • Industry report
  • April 2014
  • 8 pages
  • by Corporation

... To compare the expenditure of other chronic diseases, particularly chronic diseases that share many of the same risk factors such as ckd [14]. As a result, this investigation will determine and compare ...

U.s. Diabete Sector

April 2014

» Read our Company Profiles

About 200 Companies

GlaxoSmithKline P.L.C.

United States

Novartis Inc.

Switzerland

Pfizer Inc.

United States

Johnson and Johnson

United States

GlaxoSmithKline PLC

United Kingdom

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.